📋 Key Information Summary
- Definition: COPD is a progressive, largely irreversible airflow limitation characterised by persistent respiratory symptoms and airflow obstruction; post-bronchodilator FEV1/FVC <0.70 confirms diagnosis.
- Prevalence: Approximately 7.5% of Australians aged ≥40 years have COPD; it is the fifth leading cause of death nationally and disproportionately affects Aboriginal and Torres Strait Islander peoples.
- GOLD Classification: The GOLD 2024 ABCD framework classifies patients by spirometric severity (GOLD 1–4), exacerbation history (≥2 moderate or ≥1 hospitalised in past year), and symptom burden (mMRC ≥2 or CAT ≥10).
- First-line pharmacotherapy: LAMA (e.g. tiotropium) monotherapy for most initial presentations; LABA+LAMA combination for persistent dyspnoea or higher symptom burden (Group B/E).
- ICS use: Inhaled corticosteroids are indicated only for patients with elevated eosinophils (≥300 cells/µL) or frequent exacerbations despite LABA+LAMA; never as monotherapy in COPD.
- Triple therapy (ICS+LABA+LAMA): Reserved for patients with persistent exacerbations on dual bronchodilation with eosinophil ≥100 cells/µL; evidence from IMPACT and ETHOS trials demonstrates mortality benefit.
- Acute exacerbations: Managed with short-acting bronchodilators (SABA ± SAMA), systemic corticosteroids (prednisolone 40 mg for 5 days), and antibiotics if Anthonisen Type 1 or purulent sputum; NIV for acute hypercapnic respiratory failure.
- Pulmonary rehabilitation: Strongly recommended for all symptomatic COPD patients; reduces hospital admissions, improves exercise capacity and quality of life; available through many Australian public hospitals and community programmes.
- Smoking cessation: The single most effective intervention to slow FEV1 decline; pharmacotherapy (varenicline, NRT) combined with behavioural support achieves the highest quit rates.
- Long-term oxygen therapy (LTOT): Improves survival when PaO2 ≤55 mmHg (or ≤59 mmHg with cor pulmonale/polycythaemia); prescribed ≥15 hours/day via concentrator or cylinder — funded through the Australian Integrated Aids and Equipment Programme.
- Alpha-1 antitrypsin deficiency: Screen all COPD patients aged <45 years, those with a strong family history, or with predominantly basal emphysema on CT.
- Vaccinations: Annual influenza, pneumococcal (PCV20 or PCV15+PPV23), COVID-19, and zoster (≥50 years) — all funded under the National Immunisation Programme for eligible patients.
- ATSI considerations: COPD prevalence in First Nations Australians is 2.5 times higher; earlier onset, greater severity, and higher mortality. Culturally safe spirometry, smoking cessation, and pulmonary rehabilitation access in remote communities are essential.
Introduction & Australian Epidemiology
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterised by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation is caused by a combination of small airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary between individuals.
Australian Burden of Disease
- COPD affects approximately 1 in 13 Australians aged ≥40 years (BOLD-Australia study), with many cases remaining undiagnosed.
- It is the fifth leading cause of death in Australia and the third leading cause of disease burden in males (AIHW Burden of Disease, 2023).
- In 2021–22, COPD accounted for over 230,000 hospitalisations nationally, with a mean length of stay of 5.3 days — significantly longer than the all-cause average.
- The total economic cost of COPD in Australia is estimated at $8.9 billion annually, including direct healthcare costs, productivity losses, and informal carer burden.
- Aboriginal and Torres Strait Islander peoples experience 2.5 times the prevalence and 3 times the mortality rate of non-Indigenous Australians for COPD.
- COPD is over-represented in lower socioeconomic groups, rural and remote populations, and among current and former smokers.
Aetiology & Risk Factors
| Risk Factor | Details | Australian Context |
|---|---|---|
| Tobacco smoking | Accounts for ~70–80% of COPD cases; dose-dependent risk (pack-years) | 11.6% of Australian adults smoke daily (2022); higher in ATSI populations (~37%) |
| Occupational exposure | Dust, fumes, chemicals (10–20% of COPD) | Mining, agriculture, construction workers at elevated risk |
| Indoor air pollution | Biomass fuel combustion in poorly ventilated settings | Significant contributor in remote Indigenous communities using wood fires |
| Genetic predisposition | Alpha-1 antitrypsin deficiency (AATD) — PiZZ genotype | Estimated 1 in 2,500 Australians carry the PiZZ phenotype; under-diagnosed |
| Childhood respiratory illness | Severe childhood asthma, recurrent lower respiratory tract infections | Contributes to fixed airflow obstruction in younger adults |
| Asthma with persistent airflow limitation | Asthma–COPD overlap (ACO) phenotype | Common in Australian primary care; requires tailored management |
Diagnosis & Spirometry
The diagnosis of COPD requires a clinical history of chronic respiratory symptoms (dyspnoea, cough, sputum production) plus confirmation of persistent airflow obstruction by spirometry. Spirometry should be performed after administration of a short-acting bronchodilator (e.g. salbutamol 400 µg) to confirm that the obstruction is not fully reversible.
Critical diagnostic criterion: A post-bronchodilator FEV1/FVC ratio <0.70 confirms persistent airflow obstruction and the diagnosis of COPD. Pre-bronchodilator spirometry alone is insufficient for diagnosis.
Spirometric Severity — GOLD Staging
| GOLD Stage | Severity | Post-BD FEV1 (% Predicted) | Clinical Implications |
|---|---|---|---|
| GOLD 1 | Mild | ≥80% | Often unrecognised; mild symptoms; may not seek medical attention |
| GOLD 2 | Moderate | 50–79% | Most commonly diagnosed stage; exertional dyspnoea; usual presentation in primary care |
| GOLD 3 | Severe | 30–49% | Significant functional limitation; frequent exacerbations; specialist referral warranted |
| GOLD 4 | Very Severe | <30% | Quality of life markedly impaired; may need long-term oxygen therapy; evaluate for advanced therapies |
Differential Diagnosis: COPD vs Asthma
| Feature | COPD | Asthma |
|---|---|---|
| Age of onset | Typically >40 years | Often childhood or early adulthood |
| Smoking history | Usually ≥10 pack-years | May or may not be present |
| Symptom pattern | Persistent, progressive; morning cough productive | Episodic, nocturnal, variable; triggers identifiable |
| Airflow obstruction | Partially or not reversible | Usually fully reversible (post-BD FEV1 improves ≥200 mL and ≥12%) |
| Atopy / Eosinophilia | Variable; eosinophils may guide ICS use | Common; elevated IgE, blood eosinophils |
| HRCT chest | Emphysema, airway wall thickening | Usually normal between episodes |
Asthma–COPD Overlap (ACO): Some patients share features of both conditions. In ACO, expect: persistent airflow obstruction + significant reversibility (post-BD improvement ≥400 mL), eosinophilia ≥300, and/or personal/family history of atopy. Treat with ICS + LABA as first-line, with LAMA added as needed.
Alpha-1 Antitrypsin Screening
- Indications for screening: All patients diagnosed with COPD aged <45 years; any age if emphysema is predominantly basal (lower lobe predominant on CT); strong family history of COPD or liver disease; or unexplained liver disease in neonates/children.
- Initial test: Serum alpha-1 antitrypsin (AAT) level — if below 1.13 g/L (lower limit of normal), proceed to phenotyping by isoelectric focusing.
- Diagnosis confirmed: PiZZ, PiSZ, or PiNull phenotypes with AAT level <0.57 g/L (11 µM) confer significant risk for early emphysema.
- Management: Augmentation therapy (IV pooled AAT — available via Special Access Scheme in Australia) considered in PiZZ patients with established emphysema and FEV1 35–60% predicted; smoking cessation and vaccination are paramount.
- Family screening: First-degree relatives of confirmed AATD patients should be offered targeted testing (serum level + phenotyping).
Investigations — Diagnostic Workup
Essential
Spirometry (pre- and post-bronchodilator)
Confirms COPD diagnosis; GOLD staging. MBS item 11506. Available in most primary care practices with trained operators.
Essential
Chest X-ray (PA and lateral)
Excludes alternative diagnoses (lung cancer, pneumonia, heart failure); may show hyperinflation, flattened diaphragm, bullae. MBS item 58500.
Available
HRCT chest
Assesses emphysema distribution, bronchiectasis co-existence, lung cancer screening; essential for surgical planning. MBS item 56500.
Essential
Arterial blood gas (ABG)
Assesses baseline PaO2, PaCO2, and acid–base status; essential when SpO2 <92% or considering LTOT/NIV. Available in hospital settings.
Available
Full blood count
Polycythaemia (chronic hypoxia), eosinophil count guides ICS therapy, exclude anaemia as contributor to dyspnoea. MBS item 65070.
Available
Alpha-1 antitrypsin level and phenotyping
Screen at diagnosis in patients <45 years or with basal emphysema. Serum level by immunonephelometry; phenotyping by isoelectric focusing.
Available
6-Minute Walk Test (6MWT)
Functional capacity assessment; baseline and post-rehabilitation; predicts mortality when distance <350 m. MBS item 11503.
Risk Assessment & Classification
The GOLD 2024 report simplifies the previous ABCD tool into an ABE framework, emphasising the importance of both exacerbation risk and symptom burden in guiding initial and follow-up pharmacotherapy decisions.
Symptom Assessment Tools
Modified Medical Research Council (mMRC) Dyspnoea Scale
| Grade | Description | Significance |
|---|---|---|
| 0 | Breathless only with strenuous exercise | Low symptom burden |
| 1 | Short of breath when hurrying on level or walking up a slight hill | Low symptom burden |
| 2 | Walks slower than people of same age on level due to breathlessness, or stops for breath at own pace | Symptomatic — threshold for treatment escalation |
| 3 | Stops for breath after walking ~100 metres or after a few minutes on level | High symptom burden |
| 4 | Too breathless to leave house, or breathless when dressing/undressing | Very high symptom burden |
COPD Assessment Test (CAT)
- Eight-item questionnaire scored 0–40; assesses cough, phlegm, chest tightness, breathlessness, activity limitation, confidence leaving home, sleep, and energy.
- CAT <10 = low symptom burden; CAT ≥10 = high symptom burden.
- Use either mMRC or CAT — CAT is preferred as it captures a broader symptom profile.
GOLD 2024 ABE Classification
The GOLD 2024 update merged the former Groups C and D into a single Group E (Exacerbation risk), simplifying the classification while preserving clinical relevance.
Group A
Low Risk, Low Symptoms
0–1 moderate exacerbations/year (not hospitalised) AND mMRC 0–1 / CAT <10
Initial therapy: Bronchodilator (short- or long-acting) as needed
Group B
Low Risk, High Symptoms
0–1 moderate exacerbations/year (not hospitalised) AND mMRC ≥2 / CAT ≥10
Initial therapy: LABA + LAMA dual bronchodilation
Group E
High Exacerbation Risk
≥2 moderate exacerbations/year OR ≥1 leading to hospitalisation (symptoms may be high or low)
Initial therapy: LABA + LAMA (add ICS if eosinophils ≥300 or frequent exacerbations)
Exacerbation Risk Assessment
- Moderate exacerbation: Requires treatment with systemic corticosteroids and/or antibiotics but not hospitalisation.
- Severe exacerbation: Requires hospitalisation or presents to the emergency department.
- Very severe exacerbation: Requires ICU admission, may involve NIV or mechanical ventilation.
- Blood eosinophil count is now a key biomarker: ≥300 cells/µL predicts ICS benefit in reducing exacerbations; <100 cells/µL suggests ICS is unlikely to be helpful and may increase pneumonia risk.
Additional Prognostic Tools
| Tool | Components | Use |
|---|---|---|
| BODE Index | BMI, Obstruction (FEV1), Dyspnoea (mMRC), Exercise (6MWD) | Composite mortality predictor; score 0–10; ≥7 indicates high risk |
| DEOSS | Dyspnoea, Eosinophils, Obstruction, Smoking status, Severity of exacerbations | Australian-developed tool for exacerbation risk prediction |
| DOSE Index | Dyspnoea (mMRC), Obstruction (FEV1), Smoking status, Exacerbation frequency | Primary care screening; score ≥4 warrants specialist review |
Pharmacologic Management
Pharmacotherapy for COPD aims to reduce symptoms, improve exercise tolerance and quality of life, and reduce exacerbation frequency and severity. The GOLD 2024 strategy recommends a stepwise approach based on the ABE classification, with escalation and de-escalation guided by symptom response, exacerbation history, eosinophil count, and adverse effects.
Bronchodilator Therapy — Initial Approach
Key principle: Long-acting bronchodilators (LABA and LAMA) are preferred over short-acting agents for maintenance therapy in patients with persistent symptoms. SABA (salbutamol) and SAMA (ipratropium) should be used as reliever/rescue therapy only.
1
Group A — Low Risk, Low Symptoms
Short-acting bronchodilator PRN (SABA ± SAMA) or long-acting monotherapy (LAMA or LABA) if persistent symptoms
2
Group B — Low Risk, High Symptoms
LABA + LAMA combination from the outset; reassess in 2–4 weeks
3
Group E — High Exacerbation Risk
LABA + LAMA; add ICS if eosinophils ≥300 cells/µL or if ≥2 moderate exacerbations/year despite dual therapy
LAMA (Long-Acting Muscarinic Antagonist) Monotherapy
Tiotropium
Spiriva® · HandiHaler (18 µg capsule) or Respimat (2.5 µg, 2 puffs) · Anticholinergic (LAMA)
Adult dose
18 µg inhaled once daily via HandiHaler, OR 2.5 µg (2 puffs) once daily via Respimat
Duration
Ongoing maintenance therapy
Renal adjustment
No dose adjustment required
Hepatic adjustment
No dose adjustment required
Common adverse effects
Dry mouth, constipation, urinary retention (caution in BPH), blurred vision
PBS status
✔ PBS General Benefit
Glycopyrronium
Seebri® Breezhaler · 50 µg capsule · Anticholinergic (LAMA)
Adult dose
50 µg inhaled once daily via Breezhaler device
Duration
Ongoing maintenance therapy
Renal adjustment
No dose adjustment required
Hepatic adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
LABA + LAMA Dual Bronchodilation
Umeclidinium/Vilanterol
Anoro® Ellipta · 62.5/25 µg · LAMA + LABA combination
Adult dose
1 inhalation once daily via Ellipta device
Duration
Ongoing maintenance therapy
Renal adjustment
No dose adjustment; caution if CrCl <30 mL/min
Hepatic adjustment
No dose adjustment; caution in severe hepatic impairment
PBS status
⬤ PBS Authority Required
Tiotropium/Olodaterol
Spiolto® Respimat · 2.5/2.5 µg (2 puffs) · LAMA + LABA combination
Adult dose
2 puffs once daily via Respimat
Duration
Ongoing maintenance therapy
Renal adjustment
No dose adjustment required
PBS status
⬤ PBS Authority Required
Inhaled Corticosteroids (ICS) — Indications & Prescribing
ICS should never be used as monotherapy in COPD. ICS are associated with increased risk of pneumonia, particularly in COPD patients. Use ICS only as add-on to LABA+LAMA in patients with blood eosinophils ≥300 cells/µL, or those with frequent exacerbations despite optimised dual bronchodilation. Consider ICS withdrawal if pneumonia occurs, eosinophils <100, or no exacerbation benefit after 3–6 months.
Fluticasone furoate/Vilanterol
Breo® Ellipta · 100/25 µg or 200/25 µg · ICS + LABA
Adult dose
100/25 µg once daily (preferred in COPD); 200/25 µg if higher ICS dose needed
Duration
Ongoing; reassess ICS component every 6–12 months
PBS status
⬤ PBS Authority Required
Triple Therapy — ICS + LABA + LAMA
Triple therapy is indicated for patients with persistent exacerbations (≥2 moderate or ≥1 hospitalised) despite LABA+LAMA dual therapy AND eosinophil count ≥100 cells/µL. Landmark trials (IMPACT, ETHOS) demonstrated significant reductions in exacerbations and all-cause mortality with single-inhaler triple therapy.
Fluticasone furoate/Umeclidinium/Vilanterol
Trelegy® Ellipta · 100/62.5/25 µg or 200/62.5/25 µg · ICS + LAMA + LABA
Adult dose
100/62.5/25 µg once daily; up-titrate to 200/62.5/25 µg if needed
Duration
Ongoing; de-escalate ICS if no further exacerbations and eosinophils <100
Renal adjustment
No dose adjustment; caution if CrCl <30 mL/min
PBS status
⬤ PBS Authority Required (Specialist)
PDE4 Inhibitors
Roflumilast
Daxas® · 500 µg tablet · Phosphodiesterase-4 (PDE4) inhibitor
Adult dose
500 µg PO once daily
Indication
Severe COPD with chronic bronchitis phenotype, FEV1 <50%, and frequent exacerbations despite LABA+LAMA ± ICS
Renal adjustment
No dose adjustment required
Hepatic adjustment
Contraindicated in moderate-to-severe hepatic impairment (Child–Pugh B or C)
Common adverse effects
Diarrhoea, nausea, weight loss, headache; monitor for psychiatric symptoms
PBS status
⬤ PBS Authority Required (Specialist)
Pharmacotherapy Escalation & De-escalation Summary
| Scenario | Action | Key Considerations |
|---|---|---|
| Persistent dyspnoea on LAMA monotherapy | Escalate to LABA + LAMA | Check inhaler technique and adherence first |
| Exacerbations on LABA+LAMA, eosinophils ≥300 | Add ICS → triple therapy | Single-inhaler preferred for adherence; assess pneumonia risk |
| Exacerbations on LABA+LAMA, eosinophils 100–299 | Consider adding ICS or roflumilast | Chronic bronchitis phenotype favours roflumilast |
| Exacerbations on LABA+LAMA, eosinophils <100 | Consider roflumilast or azithromycin prophylaxis | ICS unlikely to be beneficial; macrolide via specialist |
| Pneumonia on triple therapy | Withdraw ICS; continue LABA+LAMA | Gradual withdrawal recommended; monitor for recurrence of exacerbations |
Acute Exacerbations
An acute exacerbation of COPD (AECOPD) is defined as an acute worsening of respiratory symptoms beyond normal day-to-day variation that necessitates a change in therapy. Exacerbations accelerate lung function decline, impair quality of life, and are the leading cause of COPD-related hospitalisation and mortality in Australia.
Anthonisen Criteria
Type 1
Cardinal Triad
All three cardinal symptoms present: increased dyspnoea, increased sputum volume, and increased sputum purulence
Antibiotics indicated; most likely bacterial aetiology
Type 2
Two of Three
Two of the three cardinal symptoms present (with the third being increased sputum purulence in one of the two)
Antibiotics likely indicated, especially with purulent sputum
Type 3
One of Three
Only one cardinal symptom present, plus at least one of: upper respiratory tract infection in past 5 days, fever without other cause, or increased wheeze/cough
Antibiotics usually not required; viral aetiology more likely
Antibiotic Therapy for AECOPD
Antibiotic indications in AECOPD: Prescribe antibiotics for Anthonisen Type 1 (all three cardinal symptoms), Type 2 with purulent sputum, or when mechanical ventilation (invasive or NIV) is required. Do not routinely prescribe antibiotics for mild, non-purulent exacerbations.
Amoxicillin
Amoxil® · Generic · Penicillin antibiotic
Adult dose (first-line)
500 mg PO TDS for 5 days
Paediatric dose
25–50 mg/kg/day PO divided TDS (max 500 mg TDS)
Renal adjustment
eGFR 10–30: 500 mg BD; eGFR <10: 500 mg OD
PBS status
✔ PBS General Benefit
Doxycycline
Doxy® · Generic · Tetracycline antibiotic
Adult dose (alternative first-line)
200 mg PO on day 1, then 100 mg PO daily for 4 days (5-day course)
Renal adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
Amoxicillin/Clavulanate
Augmentin® · Generic · Beta-lactam/beta-lactamase inhibitor
Adult dose (second-line)
875/125 mg PO BD for 5 days
Indication
Treatment failure with first-line agents; suspected resistant organisms
Renal adjustment
eGFR 10–30: 500/125 mg BD; eGFR <10: 500/125 mg OD
PBS status
✔ PBS General Benefit
Systemic Corticosteroids in AECOPD
Prednisolone
Panafcortelone® · Generic · Oral corticosteroid
Adult dose
40 mg PO once daily for 5 days
Key evidence
REDUCE trial demonstrated non-inferiority of 5-day vs 14-day course; 5 days is standard of care
Renal adjustment
No dose adjustment required
Caution
Monitor BSL in diabetic patients (↑ risk of hyperglycaemia); may need insulin sliding scale
PBS status
✔ PBS General Benefit
Hydrocortisone (IV)
Solu-Cortef® · Generic · IV corticosteroid
Adult dose
100 mg IV TDS initially; convert to oral prednisolone when able
Indication
Critically ill patients unable to tolerate oral medications
PBS status
✔ PBS General Benefit (hospital authority)
Short-Acting Bronchodilators (Acute Setting)
Salbutamol (SABA)
Ventolin® · Generic · Short-acting beta-2 agonist
Acute dose (nebulised)
2.5–5 mg nebulised every 20 min for 3 doses, then 2.5–5 mg every 1–4 hours as needed
Acute dose (MDI + spacer)
4–8 puffs (100 µg/puff) every 20 min for up to 4 hours, then every 1–4 hours PRN
PBS status
✔ PBS General Benefit
Ipratropium (SAMA)
Atrovent® · Generic · Short-acting muscarinic antagonist
Acute dose (nebulised)
500 µg nebulised every 20 min for 3 doses, then every 4–6 hours as needed
Role in AECOPD
May be combined with salbutamol in moderate–severe exacerbations for additive bronchodilation
PBS status
✔ PBS General Benefit
Non-Invasive Ventilation (NIV)
NIV criteria (initiate promptly): Respiratory acidosis (pH <7.35, PaCO2 >45 mmHg) despite initial medical therapy; severe dyspnoea with signs of respiratory muscle fatigue (accessory muscle use, paradoxical abdominal movement); persistent hypoxaemia despite supplemental oxygen. NIV reduces intubation rates, mortality, and ICU length of stay.
- Mode: Bilevel positive airway pressure (BiPAP) — initial settings IPAP 10–12 cmH2O, EPAP 4–5 cmH2O; titrate to achieve tidal volume 6–8 mL/kg and target SpO2 88–92%.
- Monitoring: ABG at 1–2 hours; if pH remains <7.25 or deteriorating, escalate to ICU for intubation consideration.
- Contraindications: Cardiac/respiratory arrest, inability to protect airway, undrained pneumothorax, severe haemodynamic instability, facial burns/trauma, uncooperative patient.
- Post-acute: Continue NIV for ≥4 hours initially, then wean as tolerated; aim for ≥16 hours/day until respiratory acidosis resolves.
Hospitalisation Decision Framework
| Manage in Community | Admit to Ward | Admit to HDU/ICU |
|---|---|---|
| Mild exacerbation (Type 3) | Type 1–2 exacerbation not responding to initial therapy | Severe respiratory acidosis (pH <7.25) |
| Adequate SpO2 ≥92% on room air | SpO2 <92% requiring supplemental O2 | NIV failure or need for invasive ventilation |
| Good home support and monitoring | Significant comorbidities (heart failure, diabetes) | Haemodynamic instability / shock |
| Previously mild COPD, stable baseline | Previous ICU admissions or mechanical ventilation | Altered consciousness / respiratory arrest |
Hospital in the Home (HITH) — Australian Model
- Several Australian health services offer Hospital in the Home for selected AECOPD, with IV antibiotics, nebulised bronchodilators, and daily nursing visits.
- Eligible patients: stable on initial treatment, able to manage at home with support, no requirement for continuous monitoring or NIV, adequate oxygen saturations on low-flow supplemental O2.
- Reduces hospital length of stay, hospital-acquired infections, and delirium risk; patient satisfaction is high.
Non-Pharmacologic Management
Non-pharmacological interventions are integral to comprehensive COPD management and are recommended for all patients across all GOLD stages. These interventions address exercise capacity, symptom burden, disease progression, and quality of life.
Pulmonary Rehabilitation
Strongest non-pharmacological recommendation: Pulmonary rehabilitation reduces hospital admissions, improves exercise capacity (6MWT), reduces dyspnoea, and improves quality of life (SGRQ). Recommended for all symptomatic COPD patients (mMRC ≥1) regardless of GOLD stage. Should be initiated within 2–4 weeks of hospital discharge for AECOPD.
- Programme components: Supervised exercise training (minimum 6 weeks, ideally 8 weeks), education, nutritional advice, psychosocial support, self-management strategies.
- Exercise prescription: Aerobic (walking or cycling) 20–30 min, 2–3 times/week at 60–80% peak work rate; resistance training for upper and lower limbs; flexibility and balance components.
- Australian availability: Offered through public hospitals (bulk-billed), community health centres, and some private practices. Referral pathways vary by state/territory — some require respiratory physician or GP referral.
- Maintenance: Long-term maintenance exercise following formal programme is critical to sustain benefits; community-based and telehealth options increasing across Australia.
Smoking Cessation
Varenicline
Champix® · Generic · Nicotinic acetylcholine receptor partial agonist
Dose
0.5 mg PO OD for 3 days → 0.5 mg BD for 4 days → 1 mg BD for 11 weeks (total 12-week course)
Renal adjustment
eGFR <30: 0.5 mg BD; max 1 mg/day
Efficacy
Most effective single-agent pharmacotherapy; ~33% continuous abstinence at 12 months
PBS status
✔ PBS General Benefit (2 courses per 12 months)
Nicotine Replacement Therapy (NRT)
Nicabate® · Nicorette® · Multiple formulations
Options
Patch (7, 14, 21 mg/24h), gum (2, 4 mg), lozenge (1, 2, 4 mg), inhalator, mouth spray
Combination therapy
Patch (continuous) + short-acting form (PRN) is more effective than either alone
Duration
8–12 weeks; patches can be weaned over 2–4 weeks
PBS status
⬤ PBS Authority Required (concessional only)
- Behavioural support: Combine pharmacotherapy with counselling (face-to-face, telephone via Quitline 13 7848, or digital programmes). The Australian Government funds Quitline services in all states and territories.
- A brief intervention (ABCD framework): Ask about smoking at every visit; Brief advice to quit; Counsel and assist (set quit date, provide NRT/pharmacotherapy); Do arrange follow-up.
Long-Term Oxygen Therapy (LTOT)
LTOT improves survival when used ≥15 hours/day. Criteria: resting PaO2 ≤55 mmHg (7.3 kPa), OR PaO2 56–59 mmHg (7.4–7.8 kPa) with evidence of cor pulmonale, polycythaemia (haematocrit >55%), or pulmonary hypertension. Do NOT prescribe for exertional desaturation alone without resting hypoxaemia (no survival benefit demonstrated).
- Prescription: Oxygen concentrator (primary device) ± portable oxygen cylinder for mobility; flow rate titrated to achieve SpO2 88–92% (typical 1–3 L/min via nasal prongs).
- Australian funding: Funded through the state/territory Aids and Equipment programmes (e.g. SWEP in Victoria, ILC in NSW). Patients must be assessed by a respiratory physician or thoracic medicine specialist.
- Monitoring: ABG reassessment at 60–90 days to confirm ongoing need; annual review by respiratory specialist.
- Ambulatory oxygen: Consider for patients with significant exertional desaturation who are already on LTOT and remain mobile — may improve exercise capacity.
Vaccinations
| Vaccine | Schedule | Funding |
|---|---|---|
| Influenza (annual) | Every autumn; all COPD patients | Free under NIP for all Australians ≥65 or with chronic respiratory disease |
| Pneumococcal | PCV20 (single dose) or PCV15 followed by PPV23 ≥1 year later | Free under NIP for Aboriginal and Torres Strait Islander peoples ≥50 and all adults ≥65 |
| COVID-19 | As per current ATAGI recommendations; boosters recommended for immunocompromised and elderly | Free under NIP for all eligible Australians |
| Zoster (shingles) | Shingrix® (2 doses, 2–6 months apart) for adults ≥50; preferred over Zostavax | Free under NIP for adults ≥65; ATSI ≥50 |
| Pertussis (dTpa) | One booster if not received in past 10 years | Free under NIP (catch-up); funded for pregnant women |
Nutrition
- Low BMI (<20 kg/m²): Associated with increased mortality, reduced respiratory muscle strength, and worse quality of life. Refer to a dietitian for high-calorie, high-protein nutritional support.
- Obesity (BMI ≥30): Worsens dyspnoea and exercise tolerance; weight management is important but avoid excessive calorie restriction.
- Vitamin D: Supplementation (1,000–2,000 IU daily) may reduce moderate-to-severe exacerbations in patients with baseline 25(OH)D <25 nmol/L — test and replace if deficient.
- Small, frequent meals: Reduce diaphragmatic splinting and postprandial dyspnoea; avoid carbonated drinks and gas-producing foods.
Advanced COPD
Patients with advanced COPD (GOLD 4, BODE index ≥7, frequent exacerbations despite maximal medical therapy) should be evaluated for advanced interventional therapies and palliative care. Referral to a respiratory specialist or multidisciplinary advanced lung disease service is essential.
Surgical & Interventional Options
| Intervention | Indication | Key Criteria | Australian Availability |
|---|---|---|---|
| Lung Volume Reduction Surgery (LVRS) | Upper-lobe predominant emphysema with low baseline exercise capacity | FEV1 15–45%, heterogeneous emphysema on CT, PaCO2 ≤50 mmHg, no significant pulmonary hypertension | Available at major tertiary centres (e.g. Royal Prince Alfred, Alfred Hospital, Prince Charles Hospital); Medicare-funded |
| Endobronchial Valves (EBV) | Severe heterogeneous emphysema with complete fissure and no collateral ventilation | FEV1 15–45%, hyperinflation (RV >175%), intact interlobar fissure on CT (Chartis assessment) | Available at specialised interventional pulmonology centres; TGA-approved; PBS listing pending for devices |
| Bullectomy | Giant bullae (>30% hemithorax) compressing adjacent functional lung | Relatively preserved underlying lung parenchyma; heterogeneous disease with compression effect | Available at thoracic surgery centres; may be performed via VATS |
| Lung Transplantation | End-stage COPD refractory to all other therapies | BODE 7–10, FEV1 <15–20%, frequent hospitalisations, PaCO2 >50 mmHg, pulmonary hypertension, or rapid FEV1 decline | Available at St Vincent's Hospital (Sydney), Alfred Hospital (Melbourne), Prince Charles Hospital (Brisbane); waitlist 12–24 months |
Lung Transplant Evaluation — Practical Approach
- When to refer: Consider referral when BODE index ≥7 or any single criterion suggesting rapid decline (e.g. FEV1 <20% predicted, ≥3 exacerbations/year, or FEV1 decline >40 mL/year).
- Age limits: Most Australian centres accept patients up to 65 years for single lung and 60 years for bilateral transplant; selected patients older may be considered.
- Contraindications: Active malignancy, active infection (including non-treated TB), severe skeletal deformity, non-adherence, substance abuse (must demonstrate ≥6 months abstinence), BMI >35 or <17.
- Pre-transplant workup: Comprehensive cardiopulmonary assessment, CT chest/abdomen, coronary angiography if indicated, bone densitometry, psychological and social assessment, dental review, HLA typing.
Palliative Care
Palliative care should be integrated early — not only at end of life. The Advance Care Planning Australia framework supports concurrent disease-modifying and palliative approaches. Early palliative care referral improves symptom burden, reduces futile hospitalisations, and supports goal-concordant care.
- When to refer: GOLD 4 with progressive decline, recurrent hospitalisations, refractory dyspnoea despite maximal therapy, significant symptom burden (CAT >20), patient-expressed preference for comfort-focused care.
- Symptom management: Low-dose opioids (oral morphine 2.5–5 mg BD) for refractory breathlessness; anxiolytics for associated anxiety; fan therapy; positioning and breathing techniques.
- Advance Care Planning: Document patient preferences regarding intubation, NIV, hospitalisation, and resuscitation. Use the National Advance Care Planning templates available from Advance Care Planning Australia.
- Community palliative care: Available in all Australian states and territories; referral via GP or hospital team. In remote areas, Royal Flying Doctor Service and specialist palliative care outreach programmes provide support.
Special Populations
Pregnancy
Stability is paramount: Uncontrolled COPD in pregnancy increases pre-eclampsia, preterm birth, and IUGR risk. Maintain optimal bronchodilator therapy throughout pregnancy.
LABA/LAMA: Tiotropium and formoterol have reassuring safety data in pregnancy; continue as indicated. Salbutamol is safe.
ICS: Budesonide is the preferred ICS in pregnancy (most safety data). Fluticasone also considered acceptable.
Exacerbations: Treat aggressively — maternal hypoxaemia is harmful to the foetus. Prednisolone is compatible with pregnancy; monitor for gestational diabetes.
Mandatory smoking cessation — highest priority in pregnancy. Involve multidisciplinary team including obstetrician and respiratory physician.
Paediatrics
Diagnosis: COPD is rare in children; consider cystic fibrosis, primary ciliary dyskinesia, bronchiectasis, or severe asthma as primary diagnoses. Fixed airflow obstruction in young adults may stem from childhood respiratory disease.
Alpha-1 antitrypsin deficiency: May present in childhood with liver disease; emphysema typically manifests in 30s–40s.
Congenital lung anomalies: Congenital lobar emphysema and bronchial atresia may mimic COPD in younger patients.
Asthma with persistent airflow limitation in adolescents should be managed as per asthma guidelines with ICS/LABA first-line.
Elderly
Inhaler technique: Arthritis, cognitive decline, and reduced hand strength impair device use. Select simpler devices (Respimat, Ellipta) over capsule-based inhalers when possible. Reassess technique at every visit.
Polypharmacy: Review for drug interactions (beta-blockers, anticholinergics for bladder/brain). Beers criteria — avoid first-generation antihistamines and sedating medications.
Osteoporosis: Increased risk with ICS use, smoking, sedentary lifestyle, and systemic corticosteroid courses. Dual-energy X-ray absorptiometry (DEXA) recommended; consider bisphosphonate prophylaxis.
Frailty: Comprehensive geriatric assessment for frail COPD patients; pulmonary rehabilitation adapted for elderly participants; falls prevention strategies.
Consider Advance Care Planning early; many elderly patients prioritise quality of life and symptom control over aggressive interventions.
Renal Impairment
Inhaled bronchodilators: No significant dose adjustment for LABA, LAMA, or ICS in renal impairment — drug is delivered locally with minimal systemic absorption.
Prednisolone: No dose adjustment; monitor for fluid retention and hyperglycaemia. Use lowest effective dose for shortest duration in recurrent courses.
Antibiotics: Adjust amoxicillin dose: eGFR 10–30: 500 mg BD; eGFR <10: 500 mg OD. Doxycycline does not require adjustment. Avoid gentamicin unless in ICU with therapeutic drug monitoring.
Roflumilast: No dose adjustment in renal impairment, but use with caution if eGFR <30; monitor closely.
Patients on dialysis with COPD have very high mortality — ensure integrated nephrology-respiratory care and advance care planning.
Hepatic Impairment
Inhaled agents: LABA, LAMA, and ICS do not require dose adjustment in hepatic impairment — hepatic metabolism of locally-deposited drug is minimal.
Roflumilast: Contraindicated in moderate-to-severe hepatic impairment (Child–Pugh B or C) due to impaired metabolism and risk of accumulation.
Varenicline: No dose adjustment required; monitor for hepatotoxicity in patients with pre-existing liver disease.
Alpha-1 antitrypsin deficiency: Liver disease (neonatal hepatitis, cirrhosis) is a manifestation of AATD; monitor liver function in patients with AATD phenotype.
Avoid excessive acetaminophen (paracetamol) use; ensure hepatotoxic medications are reviewed regularly.
Immunocompromised
ICS caution: Long-term ICS use in immunosuppressed patients (transplant recipients, HIV, biologic therapy) further increases infection risk, including atypical mycobacteria and invasive aspergillosis. Minimise ICS dose where possible.
Pneumocystis jirovecii prophylaxis: Consider in patients on high-dose corticosteroids (prednisolone ≥20 mg/day for ≥4 weeks) combined with other immunosuppression.
Vaccinations: Live vaccines contraindicated in severely immunosuppressed patients (use inactivated influenza, recombinant zoster). Ensure close contacts are vaccinated (cocooning strategy).
HIV-positive patients with COPD have accelerated lung function decline; regular spirometry monitoring is recommended regardless of smoking status.
Aboriginal and Torres Strait Islander Health
COPD is one of the most significant chronic conditions affecting Aboriginal and Torres Strait Islander Australians, with prevalence approximately 2.5 times that of the non-Indigenous population and mortality rates 3 times higher. The burden is greatest in remote and very remote communities, where indoor wood-fire smoke exposure, high smoking rates, early-life respiratory infections, and limited access to diagnostic and treatment services compound the disease impact.
Key recommendations: Prioritise culturally safe spirometry and early diagnosis. Fund Aboriginal Health Worker-led smoking cessation and pulmonary rehabilitation programmes. Ensure s100 medication supply chains support all remote communities. Integrate COPD management within the broader chronic disease frameworks used by Aboriginal Community Controlled Health Organisations (ACCHOs).
Monitoring & Follow-Up
Regular monitoring is essential to assess disease progression, treatment response, and complications. A structured follow-up plan should be established at the time of diagnosis and adjusted based on disease severity and stability.
Every 2–4 weeks
Following initial diagnosis or therapy change — assess inhaler technique, medication adherence, symptom response (mMRC/CAT), and adverse effects.
Every 3–6 months
Stable COPD — review symptom burden (CAT/mMRC), exacerbation frequency, inhaler technique, smoking status, exercise participation, and medication appropriateness (ICS justification based on eosinophils).
Every 6–12 months
Spirometry (annual or as indicated), blood eosinophil count, BMI, oxygen saturation assessment, vaccination status review, and referral to pulmonary rehabilitation if not yet completed.
Annually
Comprehensive review including spirometry, chest X-ray (if symptoms changed), BODE index calculation, psychosocial screening (anxiety/depression — PHQ-2/GAD-2), nutritional assessment, and advance care planning discussion.
Post-exacerbation
Review within 2–4 weeks of discharge: reassess maintenance therapy, ensure pulmonary rehabilitation referral, verify medication reconciliation, confirm follow-up oxygen requirements, and screen for post-exacerbation anxiety/depression.
Self-Management Action Plan
- All patients should have a written COPD Action Plan (similar to asthma action plans) with clear instructions for GREEN (stable), YELLOW (worsening — start prednisolone/antibiotics), and RED (severe — seek emergency care).
- Self-management education should cover recognition of exacerbation symptoms, early initiation of standby medications, correct inhaler and oxygen use, and when to call 000.
- Supported self-management (with regular follow-up) reduces hospital presentations and improves quality of life (Cochrane review evidence).
Quick Reference — Maintenance Therapy Summary
Group A (Low risk, low symptoms)
SABA PRN or LAMA or LABA
Ongoing
Reassess if symptoms persist
Group B (Low risk, high symptoms)
LABA + LAMA
Ongoing
If persistent dyspnoea, check technique/adherence
Group E (High exacerbation risk, Eos ≥300)
ICS + LABA + LAMA
Ongoing
Single-inhaler triple therapy preferred; reassess ICS need 6–12 monthly
Group E (High exacerbation risk, Eos 100–299)
LABA + LAMA ± ICS or + roflumilast
Ongoing
Chronic bronchitis phenotype → roflumilast preferred
Group E (High exacerbation risk, Eos <100)
LABA + LAMA ± roflumilast or azithromycin
Ongoing
ICS unlikely to help; macrolide via specialist supervision only
📚 References
- 1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. Available at: goldcopd.org.
- 2. Yang IA, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2024 update. Med J Aust. 2024;220(5):248–258.
- 3. Lipson DA, Barnhart F, Brealey N, et al. Once-single-inhaler triple therapy and the risk of mortality in patients with chronic obstructive pulmonary disease (IMPACT). N Engl J Med. 2018;378(18):1671–1680.
- 4. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD (ETHOS). N Engl J Med. 2020;383(1):35–48.
- 5. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD (WISDOM). N Engl J Med. 2014;371(14):1285–1294.
- 6. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease (REDUCE). JAMA. 2013;309(21):2223–2231.
- 7. Australian Institute of Health and Welfare (AIHW). Chronic obstructive pulmonary disease (COPD). Cat. no. ACM 35. Canberra: AIHW; 2023.
- 8. Australian Bureau of Statistics. National Aboriginal and Torres Strait Islander Health Survey, 2018–19. ABS Cat. no. 4715.0. Canberra: ABS; 2019.
- 9. Yang IA, Johns DP, Toelle BG, et al. Spirometry in Australian general practice: a national audit of training, equipment, and practice. Med J Aust. 2020;212(8):364–369.
- 10. McCarthy B, Casey D, Devane D, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(2):CD003793.
- 11. Stoller JK, Campos M. Alpha-1 antitrypsin deficiency. Lancet. 2023;401(10378):761–777.
- 12. National Asthma Council Australia. Australian Asthma Handbook, Version 2.2. Melbourne: NAC; 2024. [For ACO guidance].
- 13. Criner GJ, Sue R, Wright S, et al. A multicenter RCT of Zephyr endobronchial valves in heterogeneous emphysema (LIBERATE). Am J Respir Crit Care Med. 2018;198(9):1151–1164.
- 14. Toelle BG, Xuan W, Bird TE, et al. Respiratory symptoms and illness in older Australians: the Burden of Obstructive Lung Disease (BOLD) Australia study. PLoS One. 2013;8(6):e66326.
- 15. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.